Refining the role of dual checkpoint inhibition in advanced lung cancer: a single-cell approach KU Leuven
Immunotherapy has brought long-awaited progress in the treatment of an expanding array of cancer types. Specifically, anti-PD-1 immune checkpoint blockade (ICB) has become the backbone of first-line treatment of non-oncogene addicted advanced non-small cell lung cancer (NSCLC), with or without chemotherapy depending on PD-L1 expression level (based on KEYNOTE-024, KEYNOTE-089 and KEYNOTE-407). However, survival benefit is seen in a minority ...